<DOC>
	<DOCNO>NCT01485900</DOCNO>
	<brief_summary>Primary Objective : - To assess tolerability safety repeat oral ascending dos SAR407899A patient moderate chronic kidney disease ( CKD ) stable angiotensin convert enzyme-inhibitor ( ACE-I ) Secondary Objectives : - To assess patient moderate CKD effect concomitant multiple dose SAR407899A ACE-Is office 24-hr ambulatory blood pressure heart rate - The effect repeat multiple dos SAR407899A pharmacodynamic response ACE-Is ( AcSDKP ) - The pharmacokinetic profile repeat oral administration SAR407899A co-administration ACE-Is</brief_summary>
	<brief_title>Repeated Dosing Study Assess Safety Tolerability CKD-3 Patients Stable ACE-I Treatment</brief_title>
	<detailed_description>The total duration study around 8 week .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Male female patient age 18 79 Patients chronic kidney disease ( CKD3 ) Patients stable ACEI treatment ( type regimen ) least 2 month prior screen Body weight 50.0 kg 115.0 kg inclusive male , 40.0 kg 100 kg inclusive female If female , patient must permanently sterilize 3 month postmenopausal Having give write informed consent prior study . Exclusion criterion : Women child bear potential . Uncontrolled clinically relevant cardiovascular , pulmonary , gastrointestinal , metabolic , hematological , neurological , psychiatric , systemic , ocular , gynecologic ( female ) infectious disease , sign acute illness Active hepatitis , hepatic insufficiency Acute renal failure Patients require dialysis study Presence history drug hypersensitivity , allergic disease diagnose treated physician . Any history orthostatic dysregulation ( include limit neurocardiogenic syncope , postural orthostatic tachycardia syndrome ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>